Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02724371
Other study ID # MEN-15-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 1, 2016
Est. completion date January 31, 2029

Study information

Verified date June 2024
Source Mentor Worldwide, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety and effectiveness with the Mentor MemoryGel® Larger Size Ultra High Profile (UHP-L) Breast Implants.


Description:

Subjects, whose body shape is suited to a larger size implant than are currently available, will have their breasts reconstructed using the UHP-L Breast Implants either for the first time after a full mastectomy or as a revision of a previous breast reconstruction.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 400
Est. completion date January 31, 2029
Est. primary completion date January 31, 2029
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is female and is at least 18 years old - A candidate for: - Primary breast reconstruction in women at least 18 years old with surgically absent breast tissue (two-stage reconstruction [tissue expanders utilized with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm® and FlexHD® PLIABLE, utilized in a prior surgery to expand tissue for study device placement] to replace breast tissue post-mastectomy) - Revision surgery in women at least 18 years old with surgically absent breast tissue (previous reconstruction with silicone-filled or saline-filled implants or revision reconstruction requiring expansion surgery prior to surgery for study device implantation, with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm® and FlexHD® PLIABLE, utilized in a prior surgery to expand tissue for study device placement) - Subject understands and signs the Informed Consent - Subject agrees to return device to Mentor if device is explanted - Subject agrees to comply with follow-up procedures, including returning for all follow-up visits - Physician determines implant volume appropriate for the patient taking into account the subject's BMI and chest width Exclusion Criteria: - Subject is pregnant at time of enrollment - Subject is a current smoker, or has smoked within 3 months prior to enrollment, or plans to resume smoking within 3 months post-enrollment - Currently has uncontrolled diabetes (at time of screening or enrollment) - Has nursed a child within 3 months of study enrollment - Confirmed or suspected diagnosis of the following rheumatological autoimmune diseases or immune compromised status: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome - Currently has a condition that could compromise or complicate wound healing. Note, obesity alone is not an exclusion. All surgical risk factors (obesity, diabetes, smoking history, and prior radiation) should be considered in totality for proper subject selection - Infection or abscess anywhere in the body - Demonstrates tissue characteristics that are clinically incompatible with successful use of a breast implant (e.g. inadequate tissue or compromised vascularity) - Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk - Anatomic or physiologic abnormality that could lead to significant postoperative adverse events - Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure - Untreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatment - Anticipated need for use of ADM/mesh at the time of implant or implant exchange - Subject is HIV positive - Works for Mentor or the study doctor or is directly related to anyone who works for Mentor or the study doctor - Implanted metal or metal devices that make a MRI scan prohibitive, history of claustrophobia or other condition that would make a MRI scan prohibitive

Study Design


Related Conditions & MeSH terms

  • Breast Reconstruction, Revision Breast Reconstruction

Intervention

Device:
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.

Locations

Country Name City State
United States The Center for Dermatology and Plastic Surgery at Springbrook Alcoa Tennessee
United States Buckhead Plastic Surgery, P.C Atlanta Georgia
United States Adventist Health Bakersfield Bakersfield California
United States Paul Glat, MD, PC Bala-Cynwyd Pennsylvania
United States Susan E Downey MD, Inc Burbank California
United States Plastic Surgery Institute of Dayton Centerville Ohio
United States UVA Health System Charlottesville Virginia
United States The Plastic Surgery Group PC Chattanooga Tennessee
United States The Plastic Surgery Group Cincinnati Ohio
United States The Cleveland Clinic Cleveland Ohio
United States The Ohio State University Plastic Surgery Columbus Ohio
United States Houston Methodist Hospital Houston Texas
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States University of Iowa Hospitals & Clinics Iowa City Iowa
United States The University of Kansas Kansas City Kansas
United States Liu Plastic Surgery Los Gatos California
United States Abbott Northwestern Hospital Minneapolis Minnesota
United States The Centre, PC Mishawaka Indiana
United States Plastic Surgery Associates of Montgomery Montgomery Alabama
United States Vanderbilt University Medical Center Nashville Tennessee
United States The Mount Sinai Medical Center New York New York
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Mayo Clinic Arizona - Scottsdale/Phoenix (MCSB) Phoenix Arizona
United States Mosharrafa Plastic Surgery Phoenix Arizona
United States Legacy Good Samaritan Medical Center Portland Oregon
United States Washington University School of Medicine Saint Louis Missouri
United States Georgia Institute of Plastic Surgery Savannah Georgia
United States Andres Plastic Surgery Scottsdale Arizona
United States Stanford University School of Medicine Stanford California
United States Baylor Scott & White Health Temple Texas

Sponsors (1)

Lead Sponsor Collaborator
Mentor Worldwide, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation 10 years
Primary 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture 10 year
Primary 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection 10 year
Primary 10 Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation with or without replacement 10 years